PEOPLE - Inovio Biomedical makes appointment:
This article was originally published in Clinica
Executive Summary
Selective electrochemical tumour ablation (SECTA) therapy device developer Inovio Biomedical has named Michael Fons as vice-president of corporate development. SECTA is an alternative to localised surgical tumour removal. HTA, markets and IP specialist Dr Fons had been executive director at the San Diego, California company for some three years.